Physician profile
Matthew Barker
NPI 1700267481
$448.30
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $168 · 2022: $30.19 · 2023: $34.75 · 2024: $84.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71.88 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $69.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.31 | 2021-2024 | Xifaxan, Trulance |
| Adlon Therapeutics L.P. | $32.06 | 2021 | |
| Acella Pharmaceuticals, LLC | $23.12 | 2024 | NP Thyroid 60 |
| Bioventus LLC | $22.01 | 2024 | Durolane |
| Arbor Pharmaceuticals, INC. | $21.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.06 | 2019 | |
| Si-Bone, INC. | $17.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.31 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.86 | 2023 | Horizant |
| Novo Nordisk INC | $16.40 | 2022 | |
| Abbott Laboratories | $16.07 | 2021 | |
| Biogen, INC. | $14.44 | 2019 | |
| Eisai INC. | $14.34 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $12.85 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.